SEC Form SC 13G/A filed by Profound Medical Corp. (Amendment)

2/9/23 7:57:21 AM ET

Medical/Dental Instruments

Health Care

Get the next $PROF alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No. 3 PROFOUND MEDICAL CORP COMMON STOCK Cusip #74319B502 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #74319B502 Item 1: Reporting Person - FIL Limited Item 2: (a) [ ] (b) [ ] Item 4: Bermuda Item 5: 1,265,725 Item 6: 0 Item 7: 1,265,725 Item 8: 0 Item 9: 1,265,725 Item 11: 6.051% Item 12: FI Cusip #74319B502 Item 1: Reporting Person - Pandanus Partners, L.P. Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 1,265,725 Item 8: 0 Item 9: 1,265,725 Item 11: 6.051% Item 12: PN Cusip #74319B502 Item 1: Reporting Person - Pandanus Associates, Inc. Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 1,265,725 Item 8: 0 Item 9: 1,265,725 Item 11: 6.051% Item 12: CO Item 1(a). Name of Issuer: PROFOUND MEDICAL CORP Item 1(b). Address of Issuer's Principal Executive Offices: 2400 SKYMARK AVENUE, UNIT 6 MISSISSAUGA, A6 L4W 5K5 CANADA Item 2(a). Name of Person Filing: FIL Limited Item 2(b). Address or Principal Business Office or, if None, Residence: Pembroke Hall, 42 Crow Lane, Hamilton, Bermuda, HM19 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 74319B502 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FIL Limited, is a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J). (Note: See Exhibit A). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify type of institution: Parent holding or control person. Item 4. Ownership (a) Amount Beneficially Owned: 1,265,725 (b) Percent of Class: 6.051% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 1,265,725 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 1,265,725 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of PROFOUND MEDICAL CORP. The interest of Fidelity True North Fund, in the COMMON STOCK of PROFOUND MEDICAL CORP, amounted to 1,265,050 shares or 6.048% of the total outstanding COMMON STOCK at December 30, 2022. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to FIL Limited and its various non-U.S. investment management subsidiaries included on this Schedule 13G is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institutions. I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 9, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of December 19, 2022, by and on behalf of FIL Limited and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FIL Limited on January 31, 2023, accession number: 0000318989-23-000005. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Investments Canada ULC * FI * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Pandanus Partners, L.P. ("Pandanus") owns shares of FIL Limited ("FIL") voting stock. While the percentage of total voting power represented by these shares of FIL voting stock may fluctuate as a result of changes in the total number of shares of FIL voting stock outstanding from time to time, it normally represents more than 25% and less than 48.5% of the total votes which may be cast by all holders of FIL voting stock. Pandanus Associates, Inc. ("PAI") acts as general partner of Pandanus. Pandanus is owned by trusts for the benefit of members of the Johnson family, including FIL's Chairman Abigail P. Johnson, but disclaims that any such member is a beneficial owner of the securities reported on this Schedule 13G. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FIL, certain of its subsidiaries and affiliates, and other companies (collectively, the "FIL Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FIL Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 9, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of PROFOUND MEDICAL CORP at December 30, 2022. FIL Limited By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of December 19, 2022, by and on behalf of FIL Limited and its direct and indirect subsidiaries* Pandanus Partners, L.P. By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of December 19, 2022, by Pandanus Associates, Inc. on behalf of Pandanus Partners, L.P.* Pandanus Associates, Inc. By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of December 19, 2022, by and on behalf of Pandanus Associates, Inc.* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FIL Limited on January 31, 2023, accession number: 0000318989-23-000005.

Get the next $PROF alert in real time by email

Recent Analyst Ratings for

$PROF

Date	Price Target	Rating	Analyst
7/23/2024	$16.50	Buy	Lake Street
7/16/2024	$9.00 → $12.00	Hold → Buy	Stifel
11/28/2023	$11.00	Hold	Stifel
8/4/2023	$20.00 → $200.00	Strong Buy → Outperform	Raymond James
3/21/2023	$5.50 → $10.00	Buy → Hold	Jefferies
3/7/2022	$28.00 → $14.00	Outperform	Cowen & Co.
2/22/2022	$28.00 → $23.00	Strong Buy → Outperform	Raymond James

More analyst ratings

SEC Form SC 13G/A filed by Profound Medical Corp. (Amendment)

2/9/23 7:57:21 AM ET

$PROF

Medical/Dental Instruments

Health Care

Get the next $PROF alert in real time by email

Recent Analyst Ratings for

$PROF

Date	Price Target	Rating	Analyst
7/23/2024	$16.50	Buy	Lake Street
7/16/2024	$9.00 → $12.00	Hold → Buy	Stifel
11/28/2023	$11.00	Hold	Stifel
8/4/2023	$20.00 → $200.00	Strong Buy → Outperform	Raymond James
3/21/2023	$5.50 → $10.00	Buy → Hold	Jefferies
3/7/2022	$28.00 → $14.00	Outperform	Cowen & Co.
2/22/2022	$28.00 → $23.00	Strong Buy → Outperform	Raymond James

More analyst ratings

SEC Form SC 13G/A filed by Profound Medical Corp. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$PROF

SEC Form SC 13G/A filed by Profound Medical Corp. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$PROF

$PROF
Insider Purchases

CEO Menawat Arun Swarup bought $100,151 worth of shares (22,030 units at $4.55), increasing direct ownership by 4% to 587,089 units (SEC Form 4)

$PROF
SEC Filings

Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

$PROF
Press Releases

Profound Medical Honored with INOVAIT's 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease

PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women's Health

Profound Medical Announces Upcoming Investor Events

$PROF
Insider Trading

CEO Menawat Arun Swarup bought $100,151 worth of shares (22,030 units at $4.55), increasing direct ownership by 4% to 587,089 units (SEC Form 4)

$PROF
Analyst Ratings

Lake Street initiated coverage on Profound Medical with a new price target

Profound Medical upgraded by Stifel with a new price target

Stifel initiated coverage on Profound Medical with a new price target

$PROF
Leadership Updates

Profound Medical Annual General and Special Meeting of Shareholders Voting Results

Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

Profound Medical Annual General Meeting of Shareholders Voting Results

$PROF
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Profound Medical Corp.

Amendment: SEC Form SC 13G/A filed by Profound Medical Corp.